UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $889.26 Million Stake in Pfizer Inc. $PFE

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Pfizer Inc. (NYSE:PFE) by 4.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 35,713,035 shares of the biopharmaceutical company’s stock after purchasing an additional 1,517,551 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Pfizer were worth $889,255,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Horizon Financial Services LLC grew its holdings in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer in the 4th quarter valued at about $26,000. YANKCOM Partnership bought a new position in shares of Pfizer in the 4th quarter valued at about $28,000. HFM Investment Advisors LLC grew its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer in the 2nd quarter valued at about $32,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. Citigroup lifted their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Finally, HSBC lifted their price target on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Trading Up 0.1%

Shares of PFE stock opened at $26.19 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock has a market cap of $149.26 billion, a P/E ratio of 19.99 and a beta of 0.34. The stock has a 50 day simple moving average of $26.43 and a 200 day simple moving average of $26.32. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the previous year, the business earned $0.92 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date was Friday, May 8th. Pfizer’s payout ratio is currently 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.